中國(guó)科學(xué)家報(bào)告說(shuō)他們?cè)诨加薪Y(jié)腸癌的人的血液中發(fā)現(xiàn)了兩種蛋白質(zhì),，它們可能成為準(zhǔn)確預(yù)測(cè)這種疾病是否將擴(kuò)散的生物標(biāo)記,。他們的這項(xiàng)研究發(fā)表在了美國(guó)化學(xué)會(huì)的《蛋白質(zhì)組研究雜志》月刊上。
來(lái)茂德及其同事指出,，在2008年，僅美國(guó)就新出現(xiàn)了15萬(wàn)例結(jié)腸癌,，5萬(wàn)多人死于該病。然而,，接受手術(shù)治療的結(jié)腸癌患者中的一半由于癌轉(zhuǎn)移到身體其他部分而在5年內(nèi)復(fù)發(fā)。這組科學(xué)家說(shuō),，結(jié)腸癌的轉(zhuǎn)移很難探測(cè)，而且目前沒(méi)有可靠的人體化學(xué)標(biāo)記用于預(yù)測(cè)它的轉(zhuǎn)移,。
為了發(fā)現(xiàn)用于追蹤結(jié)腸癌轉(zhuǎn)移的有用的生物標(biāo)記，這組科學(xué)家比較了來(lái)自同一個(gè)結(jié)腸癌患者的原始腫瘤細(xì)胞與轉(zhuǎn)移后的細(xì)胞產(chǎn)生的蛋白質(zhì),。他們發(fā)現(xiàn)兩種蛋白質(zhì)在轉(zhuǎn)移細(xì)胞中的濃度顯著高于原始癌細(xì)胞。這組科學(xué)家說(shuō),，這兩種蛋白質(zhì)可能作為預(yù)測(cè)結(jié)腸癌轉(zhuǎn)移的血液測(cè)試的有潛力的生物標(biāo)記,，從而可以進(jìn)行更早的干預(yù)和治療。（生物谷Bioon.com）
生物谷推薦原始出處：
J. Proteome Res., 2010, 9 (1), pp 545–555 DOI: 10.1021/pr9008817
Identification of Serum Biomarkers for Colorectal Cancer Metastasis Using a Differential Secretome Approach
Hua Xue??, Bingjian L?§, Jun Zhang, Minliang Wu, Qiong Huang?, Qiang Wu#, Hongqiang Sheng?, Dongdong Wu?, Jianwen Hu and Maode Lai*?
Department of Pathology & Pathophysiology, Department of Surgical Pathology, Affiliated Women’s Hospital, Department of Clinical Pathology, Affiliated Sir Run Run Shaw Hospital, Department of Clinical Pathology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Department of Pathology, Anhui Medical University, Hefei, China, and Research Centre for Proteome Analysis, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China
Lymph node metastasis is the major concern that causes death in colorectal cancers. However, biomarkers for cancer metastasis are still lacking. In this study, we applied an LC?MS/MS-based label-free quantitative proteomics approach to compare the differential secretome of a primary cell line SW480 and its lymph node metastatic cell line SW620 from the same colorectal cancer patient. We identified a total of 910 proteins from the conditioned media and 145 differential proteins between SW480 and SW620 (>1.5-fold change). The differential expression pattern of 6 candidate proteins was validated by Western blot analysis. Among them, trefoil factor 3 and growth/differentiation factor 15, two up-regulated proteins in SW620, were further analyzed in a large cohort of clinical tissue and serum samples. Sandwich ELISA assay showed that the serum levels of both proteins were significantly higher in lymph node metastatic colorectal cancers. Receiver operating characteristic curve analysis confirmed that serum trefoil factor 3 and growth/differentiation factor 15 could provide a discriminatory diagnostic test for predicting colorectal cancer metastasis. Immunohistochemical analysis also showed that the overexpression of trefoil factor 3 or growth/differentiation factor 15 in colorectal cancer was associated with lymph node metastatic behavior. This study showed an accurate, sensitive, and robust label-free quantitation approach for differential analysis of cancer secretome. The comparison of the cancer secretome in vitro is a feasible strategy to obtain valuable biomarkers for potential clinical application. Both trefoil factor 3 and growth/differentiation factor 15 could serve as potential biomarkers for the prediction of colorectal cancer metastasis.
